Female Sexual Interest/Arousal Disorder (FSIAD): Symptoms, Causes, Diagnosis, and Treatment

Female Sexual Interest/Arousal Disorder (FSIAD) is a sexual dysfunction recognized in the DSM-5-TR (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision) characterized by a persistent or recurrent reduction in — or absence of — sexual interest and/or physical arousal. This condition represents a significant shift from earlier diagnostic frameworks, which separated desire disorders (hypoactive sexual desire disorder) from arousal disorders (female sexual arousal disorder) in women. The DSM-5-TR merged these into a single diagnosis, reflecting extensive research showing that in women, subjective desire and physiological arousal are deeply interconnected and often difficult to distinguish clinically.

It is important to understand that fluctuations in sexual interest are a normal part of life. Temporary decreases related to stress, fatigue, relationship transitions, postpartum periods, or medical illness do not constitute a disorder. FSIAD is diagnosed only when the disturbance is persistent (typically lasting at least approximately six months), causes clinically significant distress, and is not better explained by another condition, substance use, or severe relationship distress.

FSIAD can be further specified as lifelong (present since the onset of sexual activity) or acquired (developing after a period of relatively normal sexual function), and as generalized (occurring across all situations and partners) or situational (limited to certain contexts or partners). The severity can be rated as mild, moderate, or severe. These specifiers are clinically important because they guide both the assessment of underlying causes and the treatment approach.

Estimating the prevalence of FSIAD is complicated by several factors: the diagnosis is relatively new in its merged form, cultural norms around female sexuality vary widely, and many women do not report sexual concerns to healthcare providers. That said, low sexual desire is one of the most commonly reported sexual difficulties among women worldwide.

According to the DSM-5-TR, the prevalence of low sexual desire in women varies considerably based on the definition used and the population studied. When the criterion of personal distress is included — which is essential for a clinical diagnosis — estimates are lower than when simply asking about reduced desire. Research suggests that approximately 6% to 10% of women aged 18–44 and higher proportions of women aged 45–64 experience distressing low desire. The NIMH and large epidemiological studies consistently identify desire and arousal complaints as affecting roughly one in ten women when distress criteria are applied.

Prevalence tends to increase with age, though the relationship is complex. Older women may report lower desire but also less distress about it, while younger women with low desire may experience greater distress. Cultural context, relationship status, and hormonal factors (such as menopause) all influence both the experience of and distress about low sexual interest.

According to the DSM-5-TR, a diagnosis of FSIAD requires the presence of at least three of the following six symptoms, persisting for a minimum of approximately six months and causing clinically significant distress:

• Absent or reduced interest in sexual activity. This includes a noticeable decline in the motivation to initiate or engage in sexual experiences, beyond what would be expected from normal life circumstances.
• Absent or reduced sexual or erotic thoughts or fantasies. The person experiences a marked decrease or complete absence of spontaneous sexual thoughts, daydreams, or fantasies.
• Reduced or absent initiation of sexual activity and unreceptiveness to a partner's attempts to initiate. The individual rarely or never initiates sexual encounters and shows diminished responsiveness when a partner does.
• Absent or reduced sexual excitement or pleasure during sexual activity. During most (approximately 75% to 100%) sexual encounters, the person does not experience the subjective feelings of excitement or enjoyment that previously accompanied sexual activity.
• Absent or reduced sexual interest or arousal in response to internal or external sexual or erotic cues. Stimuli that previously triggered interest — such as written, visual, or verbal erotic content — no longer elicit a response.
• Absent or reduced genital or nongenital sensations during sexual activity. Physical sensations typically associated with arousal — such as genital warmth, tingling, lubrication, or general bodily sensitivity — are diminished or absent during most sexual encounters.

Warning signs that may prompt further evaluation include a persistent sense of feeling "broken" or disconnected from one's sexuality, avoidance of intimate situations, relationship conflict centered on sexual frequency, and emotional distress such as guilt, frustration, or sadness about sexual disinterest. It is critical to recognize that the presence of distress is what distinguishes a clinical condition from a normal variation in sexual interest.

FSIAD is understood through a biopsychosocial model, meaning that biological, psychological, interpersonal, and sociocultural factors all interact to produce and maintain the condition. Rarely is a single cause identified; instead, multiple contributing factors typically converge.

Biological factors:

• Hormonal changes: Declines in estrogen (particularly during perimenopause and menopause) can reduce vaginal lubrication and alter genital sensitivity. Decreased androgen levels, which can occur after oophorectomy (surgical removal of the ovaries), adrenal insufficiency, or as part of natural aging, are associated with reduced sexual desire.
• Medications: Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), commonly prescribed for depression and anxiety, are well-documented causes of reduced sexual desire and arousal. Hormonal contraceptives, antihypertensives, and antipsychotics can also contribute.
• Medical conditions: Diabetes, cardiovascular disease, neurological conditions (such as multiple sclerosis), chronic pain, and endocrine disorders can impair sexual function through vascular, neurological, or hormonal mechanisms.
• Fatigue and sleep disorders: Chronic sleep deprivation and conditions like obstructive sleep apnea are associated with diminished sexual interest.

Psychological factors:

• Depression and anxiety: These are among the strongest psychological predictors of low sexual interest. The relationship is bidirectional — mood disorders reduce desire, and sexual dysfunction worsens mood.
• History of sexual trauma or abuse: Past experiences of sexual violence, childhood sexual abuse, or other traumatic events can profoundly affect sexual interest, arousal, and comfort with intimacy.
• Body image and self-esteem: Negative body image and low sexual self-confidence are consistently linked to reduced desire and arousal.
• Stress: Chronic life stress — from work, caregiving, finances, or other sources — depletes the cognitive and emotional resources that support sexual interest.

Interpersonal and relational factors:

• Relationship quality: Emotional disconnection, unresolved conflict, poor communication, and lack of trust are major contributors. Desire does not exist in a relational vacuum.
• Partner sexual dysfunction: A partner's sexual difficulties (such as erectile dysfunction or premature ejaculation) can reduce a woman's arousal and interest.
• Discrepancy in desire: When partners have significantly different levels of desire, the lower-desire partner may feel pressured, leading to further avoidance.

Sociocultural factors:

• Restrictive cultural or religious messages about female sexuality, inadequate sex education, and societal expectations about women's sexual roles can all contribute to inhibited sexual interest and arousal. Internalized beliefs that women "shouldn't" feel strong desire can suppress natural sexual responses.

Diagnosis of FSIAD is a clinical process conducted by a qualified healthcare provider — typically a psychiatrist, psychologist, gynecologist, or sexual medicine specialist. There is no blood test, imaging study, or single questionnaire that definitively diagnoses the condition. Instead, diagnosis relies on a comprehensive clinical interview.

The diagnostic process typically includes:

• Detailed sexual history: The clinician asks about the onset, duration, and context of symptoms, including whether the problem is lifelong or acquired, generalized or situational. Questions address frequency of sexual activity, subjective experience of desire and arousal, presence of fantasies, and response to erotic stimuli.
• Assessment of distress: Because distress is a required criterion, the clinician explores how the symptoms affect the individual emotionally, relationally, and in terms of overall quality of life. If a woman has low desire but experiences no distress about it, a diagnosis of FSIAD is not appropriate.
• Medical history and physical examination: A thorough medical review screens for hormonal abnormalities (thyroid dysfunction, menopausal status, androgen levels), chronic illnesses, surgeries (especially gynecological), and medication side effects. A pelvic examination may be conducted to rule out conditions like vulvodynia, vaginal atrophy, or pelvic floor dysfunction that could contribute to reduced arousal.
• Psychiatric and psychological assessment: Screening for depression, anxiety, PTSD, and other mental health conditions is essential, as these frequently co-occur with and contribute to sexual dysfunction.
• Relationship assessment: The quality of the individual's intimate relationship is evaluated, including communication patterns, emotional intimacy, and any history of partner violence or coercion.
• Use of validated instruments: Standardized questionnaires such as the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale–Revised (FSDS-R) can supplement the clinical interview by providing quantitative measures of sexual function and associated distress.

Differential diagnosis is important. The clinician must rule out other conditions that better account for the symptoms, including substance/medication-induced sexual dysfunction, another medical condition, another mental disorder (such as major depressive disorder where low desire is a symptom), or severe relational distress. FSIAD is not diagnosed when low desire is considered a normal adaptive response to adverse life circumstances.

Treatment for FSIAD is most effective when it is individualized, multimodal, and addresses the specific contributing factors identified during assessment. Both psychological and pharmacological interventions have demonstrated efficacy, and combined approaches are often recommended.

Psychological and behavioral treatments:

• Cognitive-behavioral therapy (CBT): CBT for sexual dysfunction targets maladaptive thoughts about sex (e.g., "I'm broken," "I shouldn't need to feel desire"), performance anxiety, and avoidance behaviors. It also addresses body image concerns and helps individuals develop a more flexible cognitive relationship with their sexuality. Research supports CBT as an effective intervention for improving desire, arousal, and sexual satisfaction.
• Mindfulness-based interventions: Developed and studied extensively by researchers such as Dr. Lori Brotto, mindfulness-based cognitive therapy (MBCT) adapted for sexual dysfunction has shown strong results. These interventions train women to direct non-judgmental attention to physical sensations during sexual activity, reducing the cognitive distraction ("spectatoring") that inhibits arousal. Multiple clinical trials demonstrate significant improvements in desire, arousal, and sexual distress.
• Sex therapy and sensate focus: Structured sex therapy, often incorporating sensate focus exercises (originally developed by Masters and Johnson), helps couples reconnect physically in a low-pressure, graduated manner. By temporarily removing the goal of intercourse or orgasm and focusing on sensory pleasure, these exercises can rebuild comfort, intimacy, and arousal.
• Couples therapy: When relational factors are significant contributors, couples therapy addressing communication, emotional intimacy, conflict resolution, and sexual scripts is an important component of treatment.

Pharmacological treatments:

• Flibanserin (Addyi): Approved by the FDA in 2015 for premenopausal women with acquired, generalized FSIAD (described at the time as hypoactive sexual desire disorder), flibanserin is a daily oral medication that acts on serotonin receptors. Clinical trials showed a modest but statistically significant increase in satisfying sexual events and desire, with a decrease in distress. Side effects include dizziness, sleepiness, nausea, and hypotension — and it cannot be used with alcohol. Its clinical benefit is considered modest, and it requires daily use.
• Bremelanotide (Vyleesi): Approved by the FDA in 2019 for premenopausal women with acquired, generalized FSIAD, bremelanotide is a melanocortin receptor agonist administered as a subcutaneous injection at least 45 minutes before anticipated sexual activity. Trials showed improvements in desire and reductions in distress. Common side effects include nausea, flushing, and injection-site reactions.
• Hormone therapy: For postmenopausal women, local or systemic estrogen therapy can address vaginal atrophy, dryness, and discomfort that impair arousal. Transdermal testosterone, while not FDA-approved for women in the United States, is used off-label and is recommended by the International Society for the Study of Women's Sexual Health (ISSWSH) for postmenopausal women with FSIAD when other factors have been addressed. Research supports its efficacy for improving desire, though long-term safety data remain limited.
• Medication review: If an SSRI or another medication is identified as a contributing factor, strategies may include dose reduction, switching to an antidepressant with fewer sexual side effects (such as bupropion), or adding an adjunctive medication. These decisions should always be made in collaboration with the prescribing provider.

Other approaches:

• Psychoeducation: Providing accurate information about female sexual response — including the recognition that responsive desire (desire that arises in response to arousal rather than preceding it) is normal — can itself be therapeutic, reducing self-pathologizing.
• Lifestyle modifications: Addressing chronic stress, improving sleep, increasing physical activity, and reducing alcohol use can create a more favorable physiological and psychological environment for sexual interest.

The prognosis for FSIAD varies depending on the underlying causes, the duration of the condition, and the individual's engagement with treatment. Many women experience meaningful improvement with appropriate intervention, particularly when treatment is comprehensive and targets the specific biopsychosocial factors at play.

Women with acquired FSIAD — especially when a clear precipitant is identified (such as a medication, a life stressor, or a relationship change) — generally have a more favorable prognosis than those with lifelong presentations. When the precipitating factor is modifiable (e.g., switching medications, addressing depression, improving relationship quality), improvements in desire and arousal can be substantial.

Lifelong FSIAD can be more challenging to treat but still responds to intervention. Mindfulness-based therapy and CBT have demonstrated sustained improvements even in women with long-standing difficulties. The key is setting realistic expectations: treatment does not aim to produce a specific frequency of sexual activity but rather to help the individual experience desire and arousal in a way that is personally satisfying and distress-free.

Recovery is often not linear. Sexual interest is influenced by an ongoing interplay of biological, psychological, and relational factors that shift over time. Maintenance strategies — including ongoing communication with partners, continued mindfulness practice, and periodic check-ins with a therapist — help sustain gains. Some women may need intermittent treatment across different life stages (e.g., postpartum, perimenopause, after a major life transition).

It is worth emphasizing that there is a wide range of normal sexual desire among women. The goal of treatment is not to achieve a particular standard but to reduce distress and enhance sexual well-being as defined by the individual.

FSIAD frequently co-occurs with and must be differentiated from several related conditions:

• Major depressive disorder (MDD): Low sexual interest is a core symptom of depression. When sexual dysfunction occurs exclusively during depressive episodes and resolves with mood improvement, a separate diagnosis of FSIAD may not be warranted. However, the two conditions often coexist independently.
• Generalized anxiety disorder and other anxiety disorders: Anxiety, hypervigilance, and cognitive preoccupation can inhibit sexual arousal. Performance-related anxiety about sexual encounters further compounds the problem.
• Posttraumatic stress disorder (PTSD): PTSD — particularly following sexual trauma — is strongly associated with sexual dysfunction, including diminished desire, arousal difficulties, and avoidance of sexual activity.
• Genito-pelvic pain/penetration disorder: Pain or fear of pain during intercourse frequently leads to reduced desire and avoidance. Pain and desire difficulties often co-occur and require integrated treatment.
• Female orgasmic disorder: Difficulty reaching orgasm and lack of desire/arousal are distinct but frequently overlapping conditions. Persistent anorgasmia can reduce motivation for sexual activity over time.
• Substance/medication-induced sexual dysfunction: When sexual dysfunction is primarily attributable to a substance (e.g., alcohol, opioids) or medication (e.g., SSRIs), the appropriate diagnosis is substance/medication-induced sexual dysfunction rather than FSIAD.
• Endocrine disorders: Hypothyroidism, hyperprolactinemia, and adrenal insufficiency can produce symptoms that mimic FSIAD and should be ruled out through appropriate laboratory evaluation.

Consider seeking professional evaluation if you experience any of the following:

• A persistent decline in sexual interest or arousal that lasts for several months or longer and is distressing to you.
• Avoidance of sexual activity that is causing conflict in your relationship or emotional pain.
• A noticeable change in sexual interest following the start of a new medication, a medical diagnosis, or a surgical procedure.
• Feelings of guilt, shame, sadness, frustration, or inadequacy related to your sexual life.
• Physical symptoms during sexual activity — such as vaginal dryness, pain, or numbness — that were not previously present.
• Co-occurring symptoms of depression, anxiety, or trauma that may be contributing to your sexual concerns.

Where to start: A primary care physician, gynecologist, or psychiatrist can conduct an initial assessment and refer you to a specialist if needed. Certified sex therapists (credentialed through organizations like AASECT — the American Association of Sexuality Educators, Counselors, and Therapists) have specialized training in sexual dysfunction. Sexual medicine clinics that offer multidisciplinary teams — including physicians, psychologists, and pelvic floor physical therapists — can provide the most comprehensive care.

It is important to know that sexual concerns are legitimate medical and psychological issues deserving the same clinical attention as any other health concern. Many women hesitate to bring up sexual difficulties with their healthcare providers, and many providers do not routinely ask. Advocating for yourself by raising the topic is a valuable first step toward getting the help you need.